Andere Sprachen Sirnaomics Ltd.

Aktien

A3DFAH

KYG2050P1028

2257

Verzögert Hong Kong S.E. Andere Börsenplätze 10:08:20 14.05.2024			% 5 Tage	% 1. Jan.
7,65 ^HKD	+5,37 %		+1,06 %	-78,63 %

10.05.	Sirnaomics Ltd. ernennt Edward Yongxiang Wang zum Executive Director	CI
16.04.	Sirnaomics Ltd. erhält von der FDA eine spezifische Empfehlung für die weitere Entwicklung des neuartigen siRNA-Therapeutikums STP705 zur Behandlung des Plattenepithelkarzinoms in situ	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director	10.05.
Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment	17.04.
Sirnaomics Ltd. Receives FDA Specific Guidance for Further Development of novel siRNA therapeutic, STP705 for Treatment of Squamous Cell Carcinoma in situ	16.04.
Sirnaomics Announces 2023 Annual Results	28.03.
Sirnaomics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference	12.03.
Sirnaomics Chairman Disposes of Shares	08.03.
Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024	05.02.
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors	24.01.
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20.12.
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770	18.12.
Sirnaomics Gets US FDA Nod for Clinical Trial of RSV Drug	18.12.
Sirnaomics Concludes First Cohort of Phase 1 Anticoagulant Drug Study	06.12.
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	05.12.
Sirnaomics Ltd. Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	05.12.
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer	04.12.
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer	01.12.
Sirnaomics Ltd. Announces Executive Changes	30.11.
Sirnaomics Shows Positive Effects of Focal Fat Reduction Drug at US Conference	02.11.
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sirnaomics Ltd.

Aktien

A3DFAH

KYG2050P1028

2257

Andere Sprachen

Filter